RBC Capital Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Cuts Target Price to $630
Barclays Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $684
Barclays Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
BTIG Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Cuts Target Price to $560
BTIG Keeps Their Buy Rating on Intuitive Surgical (ISRG)
Morgan Stanley Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $650
Evercore ISI Adjusts Price Target on Intuitive Surgical to $510 From $580, Maintains In Line Rating
Intuitive Surgical's Diversified Growth and Technological Advancements Highlight Buy Rating
Goldman Sachs Adjusts Price Target to Intuitive Surgical to $588 From $637, Keeps Buy Rating
Truist Financial Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
Wells Fargo Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $687
Intuitive Surgical's SP Stapler FDA Clearance Boosts Buy Rating: A Strategic Expansion in Thoracic and Colorectal Markets
Morgan Stanley Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $650
Intuitive Surgical Price Target Cut to $600.00/Share From $707.00 by Baird
Intuitive Surgical Is Maintained at Outperform by Baird
William Blair Maintains Intuitive Surgical(ISRG.US) With Buy Rating
Truist Financial Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Cuts Target Price to $605
Erste Group Downgrades Intuitive Surgical(ISRG.US) to Hold Rating
Intuitive Surgical Analyst Ratings
Truist Securities Maintains Buy on Intuitive Surgical, Lowers Price Target to $605